When should my osteoporosis medication be reviewed?
In the UK, the timing for an osteoporosis medication review depends largely on the specific drug you are taking and your individual risk of fracture. While some medications require a formal clinical reassessment every few years, others involve regular monitoring of your blood and kidney function every few months. A review by your GP or specialist is not just a routine check; it is a vital step to ensure the treatment is still effective, to manage any side effects, and to decide if you are a candidate for a “treatment holiday.”
What We’ll Discuss in This Article
- Typical review milestones for common bone medications
- The importance of the 3-to-5-year reassessment
- Regular monitoring requirements for injections and infusions
- Why a new fracture or side effects should trigger an early review
- The role of repeat DEXA scans and FRAX assessments
- Current UK clinical guidance for long-term skeletal health
Standard review timelines by medication type.
UK clinical guidelines, including those from NICE and the Royal Osteoporosis Society, set specific milestones for evaluating how well a medication is working.
| Medication Type | Typical Review Milestone |
| Oral Bisphosphonates (e.g., Alendronic acid) | After 5 years of treatment. |
| IV Bisphosphonates (e.g., Zoledronic acid) | After 3 annual infusions. |
| Denosumab (Prolia) | Every 3 to 5 years (with 6-monthly safety checks). |
| Anabolic Drugs (e.g., Teriparatide) | At the end of the 2-year maximum course. |
For bisphosphonates, the 5-year mark (or 3 years for infusions) is a critical point. Because these drugs stay in the bone for a long time, your GP will use this review to decide if the medication can be safely paused, a “treatment holiday”, to reduce the risk of rare long-term side effects while maintaining protection.
Regular safety monitoring between major reviews.
While a formal “treatment review” happens every few years, some medications require more frequent monitoring to ensure they are being administered safely.
- Denosumab (Prolia): Because this is a 6-monthly injection, you will typically have a review with a nurse or GP every six months. In the UK, it is standard practice to check your calcium and kidney function before each dose to ensure it is safe to proceed.
- Early Adherence Checks: For those starting oral tablets, the NHS often recommends a review at 3, 6, and 12 months to check if you are tolerating the medication and taking it correctly (e.g., staying upright and taking it on an empty stomach).
When should you request an early review?
You do not always have to wait for the 5-year milestone. You should contact your GP surgery for a medication review if:
- You suffer a new fracture: Breaking a bone while on treatment does not always mean the drug isn’t working, but it warrants a clinical evaluation.
- Side effects become unmanageable: If you experience persistent indigestion, bone pain, or other concerns, your GP can discuss alternative formulations.
- A change in health or medication: Starting new treatments (like steroids) or developing new health conditions can change your fracture risk profile.
- Dental work is planned: If you require a tooth extraction or major dental surgery, you should inform your GP and dentist, as bone medications can occasionally affect jaw healing.
What happens during a formal treatment review?
When your GP or specialist performs a formal review, they aren’t just looking at your prescription. They will typically re-evaluate your “Fracture Risk” using two primary tools:
- FRAX or QFracture: These are UK-validated calculators that use your age, weight, and health history to predict your 10-year risk of a major fracture.
- Repeat DEXA Scan: A follow-up bone density scan is often organised at the 3-to-5-year mark. Your GP will compare this to your baseline scan to see if your bone mineral density has increased, stayed stable, or declined.
Based on these results, your GP will decide whether to continue the current treatment for another 5 years, switch to a different drug, or begin a treatment holiday.
Conclusion
Your osteoporosis medication should be reviewed by your GP at least every 5 years for oral tablets and every 3 years for annual infusions. For injections like denosumab, safety monitoring occurs every six months, with a broader clinical review every 3 to 5 years. These reviews are essential for ensuring your skeleton remains protected while minimising the risk of long-term side effects. If you have any concerns about your treatment or experience a new injury, you should request an appointment sooner. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Do I need a DEXA scan every year?
No, bone density changes slowly. In the UK, repeat scans are usually performed every 3 to 5 years during treatment, rather than annually.
Can I have a “treatment holiday” from Denosumab?
No, unlike bisphosphonates, the effects of Denosumab wear off quickly. Stopping it without a follow-up plan can lead to a rapid loss of bone density.
Will my GP automatically call me for a review?
While many surgeries have automated reminders, it is a good idea to keep track of your own start date and prompt your GP when you approach the 5-year mark.
What if my bone density hasn’t improved at the review?
If your density is stable, the treatment is often considered a success. If it has declined, your GP may investigate other factors like vitamin D levels or malabsorption.
Is an annual flu jab a good time for a bone review?
While not a formal review, it’s a great opportunity to ask your GP or pharmacist if your bone health monitoring is up to date.
What is the “Upright Rule” review?
During your first year, your GP or pharmacist may check that you are taking your tablets correctly, staying upright for 30–60 minutes, to prevent oesophageal irritation.
Can I switch from tablets to injections at my review?
Yes; if you are struggling with the weekly tablet routine or indigestion, a review is the perfect time to discuss switching to a 6-monthly injection or yearly infusion
Authority Snapshot (E-E-A-T Block)
This article examines the clinical protocols for medication reviews within the UK’s primary care system. It has been written and reviewed by Dr. Stefan Petrov, a UK-trained physician, to ensure the information is accurate and reflects current NHS, NICE, and Royal Osteoporosis Society standards. The content is designed to help patients take an active role in their long-term bone health management.
